Gao L, et al. - The fibroblast growth factor 19 (FGF19)-mediated mechanism affecting sorafenib treatment has been explored in this study. Data suggested a critical role of the FGF19-FGFR4 axis in the effects elicited by sorafenib in hepatocellular carcinoma (HCC) cells. In the treatment of patients with HCC, blocking the FGF19-FGFR4 axis could provide novel opportunities to improve the efficacy of sorafenib.